Phase I Study of TAS-120 in Patients with Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Patients with advanced solid tumors
- Registration Number
- JPRN-jRCT2080222501
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 142
Inclusion Criteria
1. Provided written informed consent for treatment.
2. 20 years of age or older at enrollment.
3. Histologically or cytologically confirmed advanced or metastatic solid tumor(s) without standard treatment remains.
4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 on time of patient's allocation.
Exclusion Criteria
1. A serious illness or medical conditions.
2. Known hypersensitivity to any drugs similar to TAS-120 in structure or class.
3. Pregnant or lactating female or women of child-bearing potential who have a positive pregnancy test (urine or serum) within 7 days prior to starting the study drug.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method